|
|
Last Modified: 1/29/2008  First Published: 12/8/2006 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase IV, Phase III
|
|
|
|
Treatment
|
|
|
|
Active
|
|
|
|
21 and under
|
|
|
|
Other
|
|
|
|
GPOH-NB2004 EU-20661, NCT00410631
|
|
|
|
|
|
|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II, Phase I
|
|
|
|
Treatment
|
|
|
|
Active
|
|
|
|
18 and over
|
|
|
|
Pharmaceutical / Industry
|
|
|
|
MIP-IB12 NCT00458952
|
|
|
|
|
|
|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II, Phase I
|
|
|
|
Treatment
|
|
|
|
Active
|
|
|
|
1 to 14
|
|
|
|
Other
|
|
|
|
87-01-36-6853 NCT00798148
|
|
|
|
|
|
|
|
Last Modified: 7/17/2007  First Published: 3/24/2005 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Treatment
|
|
|
|
Active
|
|
|
|
Over 1
|
|
|
|
Other
|
|
|
|
MSKCC-04148 NCT00107289
|
|
|
|
|
|
|
|
Last Modified: 12/10/2008  First Published: 11/4/2005 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Treatment
|
|
|
|
Active
|
|
|
|
1 to 29
|
|
|
|
NCI
|
|
|
|
NANT-2001-02 NCT00253435
|
|
|
|
|
|
|
|
Last Modified: 11/5/2008  First Published: 7/24/2007 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase I
|
|
|
|
Treatment
|
|
|
|
Active
|
|
|
|
1 to 30
|
|
|
|
NCI
|
|
|
|
NANT-2004-06 NANT N2004-06, NANT-N04-06, NANT-Draximage-2007-01, NCT00509353
|
|
|
|
|
|
|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
No phase specified
|
|
|
|
Biomarker/Laboratory analysis, Diagnostic
|
|
|
|
Active
|
|
|
|
Not specified
|
|
|
|
Other
|
|
|
|
000093 00-CH-0093, NCT00004847
|
|
|
|
|
|
|
|
Last Modified: 10/2/2007  First Published: 8/30/2007 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
No phase specified
|
|
|
|
Treatment
|
|
|
|
Active
|
|
|
|
6 months to 21
|
|
|
|
Other
|
|
|
|
GPOH-NB2004-HR NB2004-HR, UNI-KOELN-161, NCT00526318
|
|
|
|
|
|
|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
No phase specified
|
|
|
|
Treatment
|
|
|
|
Active
|
|
|
|
6 months to 21 years
|
|
|
|
Other
|
|
|
|
385/2005 NCT00790413
|
|
|
|